In an in vivo xenograft model, SLC3A2-targeted CAR-T cells significantly improved overall survival and reduced subcutaneous xenograft tumor growth and tumor burden without weight loss and cytokine release syndrome (CRS) (50). This evidence concerns the gene SLC3A2 and neoplasm.